This study is looking at how a drug called belzutifan affects certain proteins in people with advanced clear cell kidney cancer (renal cell carcinoma or RCC). You may be able to join if you have advanced clear cell RCC that has gotten worse after prior immunotherapy. Researchers will give you belzutifan daily for 28 days and a single dose of 89Zr-DFO-girentuximab, which helps them see specific proteins using a special scan (PET scan). The main goal is to see if belzutifan changes the amount of these proteins in your tumors and to check for any serious side effects after 4 weeks. This is the first study to explore these changes, hoping to find new ways to combine treatments in the future. The study aims to enroll 12 participants, but its current status is unclear.

Study design

This is an interventional study with a planned enrollment of 12 participants. It is designed to evaluate changes in protein levels and side effects after treatment.

What's involved

You would take belzutifan daily for 28 days and receive one slow intravenous (IV) dose of 89Zr-DFO-girentuximab. You would have PET scans before and after 4 weeks of treatment.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints are measured at baseline and after 4 weeks of treatment with belzutifan.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.